The U.S. House Judiciary Committee has voted to approve a drug pricing bill that will pave the way for biosimilar drugs to be brought to market. It’s one of several measures in a drug-pricing package introduced in April. (Reuters)

The Biden administration and public health officials continue to debate the need for booster shots in advance of an expected winter COVID-19 surge. Tension between top COVID-19 advisors is emblematic of the confusion over whether booster shots are needed for the general population. (Politico)

After several failed studies, GlaxoSmithKline and Merck KGaA ended their $4 billion partnership on cancer drug bintrafusp alfa. GSK will continue focusing on its immuno-oncology portfolio, the company said. (Endpoints News)

Merck plans to seek out additional acquisitions after buying Acceleron Pharma for $11 billion, CEO Rob Davis said. The company plans to invest in its experimental drugs as it prepares for blockbuster cancer drug Keytruda to face generic competition. (STAT)

Startup Stellar Health has raised $60 million from investors General Atlantic and Oak Street Health founders. The company aims to provide a better and more flexible value-based care experience. (Business Insider)